Condition: Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients · Metastatic Colorectal Cancer (CRC) · Peripheral Neuropathy Due to Chemotherapy · Sponsor: Fox Chase Cancer Center
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
This description comes directly from the study's public registry record.
Namrata Vijayvergia, MD · 2152141676 · Namrata.Vijayvergia@fccc.edu
Henkel Valentine, PhD · 2152141600 · henkel.valentine@fccc.edu
Always discuss trial participation with your own doctor first.
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07167446